The Company
EndoGI is a medical device company developing a Multiple Stents Placement Delivery System for the treatment of biliary and pancreatic ducts stenosis and strictures.
EndoGI system enables insertion and placement of two stents or more in the common bile and hepatic ducts with one passage of the delivery system while securing and maintaining access of the guide wire at the targeted anatomical site.
The Need
Blockage of the Bile duct
- Bile dismantles fats in the gastrointestinal tract.
- It produced in the liver, stored in the gallbladder and secreted through the bile ducts to the small intestine.
In case of bile duct stenosis as a result of cancer/injury/Inflammation/Cholangitis or Gallstones there is an urgent need in using biliary stent for bile drainage.
The Solution - System
Multiple Stents Placement through one passage
Allowing:
- Bigger drainage diameter like in Self Expandable Metal Stent
- Easier removal like in Plastic Stent
- Cost Affordable Solution
- Easier Procedures steps and Usability
- Maintaining and securing Guidewire location
The Market
Estimated 1 million procedures with annual growth rate of 7.3%.
The US market holds 40% of the global market.
The stents market growth dynamics:
- Significant increase in the incidence of pancreatic cancer and associated diseases of the liver
- The use of bile stents for palliative care in bile duct obstruction is continuously increased
- Awareness of the advantages of drainage and the opening of blockages in patients with chronic pancreatitis and pancreatic cancer will lead to a significant increase in the use of stents.
http://www.global-market-research-data.com)/
Management Team:
Omri Naveh - CEO, Omri Naveh has experience in R&D and Engineering management position.Omri led products through FDA approvals, NPI processes and mass production.Previous companies: Lumenis and ETView
Elad Einav - Co-Founder, Director & Chief Technology Officer, Elad Einav has over 10 years of experience in R&D, Clinical &Regulatory and management positions.Elad led products through FDA and CE approvals to scalability and commercialization (CEO at MediBrane, Biovo).
Ronny Barak - Co-Founder, Director &Strategic Business Development, Ronny Barak has over 20 years of experience in the Life Science industry. Ronny led as CEO medical device companies to acquisition, strategic partnership and IPO. (CEO at Disc-O-Tech, CollPlant, EndoGun-IBI)
Zohar Gendler, M.Sc. – Director & NGT3VC CEO ,Former CEO and director of Beta-O2 Technologies. Served as CEO of the Technion Entrepreneurial Incubator for a period of 11 years. Zohar led the establishment and investment in more than 40 companies.
